Key Highlights

  • Shares are trading down about 7.01% today, recovering from a steeper early decline.
  • A short-seller research firm disclosed a short position and alleged improper Medicaid billing.
  • The report cited an undisclosed 2024 Tennessee fraud-referral inquiry.
  • The company has not yet responded publicly to the allegations.
  • The company separately confirmed it will present at a healthcare investor conference on December 1.

BillionToOne (NASDAQ:BLLN) shares are trading lower today after a short-seller research firm disclosed a short position and published a report alleging improper Medicaid billing practices. BillionToOne is a molecular diagnostics company whose proprietary counting platform powers its UNITY prenatal screening test, its primary Revenue driver, alongside liquid biopsy tests used in oncology therapy selection and cancer monitoring.

Report Alleges Billing Issues and a 2024 Fraud Inquiry

The report alleged an undisclosed 2024 Tennessee fraud-referral inquiry and claimed the company engaged in aggressive bundling of carrier screening with prenatal tests. The claims have not been independently established, and the company had not yet responded publicly to the allegations as of today's session.

Shares Recover From a Steeper Intraday Decline

Shares touched an intraday low near $85.71, down roughly 12%, before recovering part of the drop on above-average volume. The selloff follows a recent stretch in which the stock had posted a strong third-quarter beat-and-raise, with several research firms maintaining bullish ratings ahead of a scheduled investor conference appearance.

Upcoming Conference Appearance Still on the Calendar

Separately from today's selloff, the company confirmed that management will participate in a fireside chat at a major healthcare investor conference on December 1, an appearance that could give the company its next opportunity to directly address the allegations publicly.

Mixed Sector Backdrop Adds Context to the Decline

Today's decline also comes against a mixed sector backdrop, with broader healthcare sentiment affected by a separate proposed CMS rule tightening fraud and audit oversight across government health programs. Investors are likely to watch for the company's formal response to the allegations as the next catalyst for the stock.